Byrne Asset Management LLC Arcutis Biotherapeutics, Inc. Transaction History
Byrne Asset Management LLC
- $116 Million
- Q2 2024
A detailed history of Byrne Asset Management LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Byrne Asset Management LLC holds 100 shares of ARQT stock, worth $1,381. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$1,381
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$161 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$151 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$148 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$121 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$119 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $831M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...